BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 17852463)

  • 1. New insights into paroxysmal nocturnal hemoglobinuria.
    Savage WJ; Brodsky RA
    Hematology; 2007 Oct; 12(5):371-6. PubMed ID: 17852463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria.
    Brodsky RA
    Blood Rev; 2008 Mar; 22(2):65-74. PubMed ID: 18063459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into paroxysmal nocturnal hemoglobinuria.
    Brodsky RA
    Hematology Am Soc Hematol Educ Program; 2006; ():24-8, 516. PubMed ID: 17124035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
    Risitano AM; Perna F; Selleri C
    Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Paroxysmal nocturnal hemoglobinuria (PNH). Pathogenesis, diagnosis and treatment].
    Röth A; Dührsen U; Schrezenmeier H; Schubert J
    Dtsch Med Wochenschr; 2009 Feb; 134(9):404-9. PubMed ID: 19224425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
    N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria.
    Hill A; Rother RP; Hillmen P
    Haematologica; 2005 Dec; 90(12 Suppl):ECR40. PubMed ID: 16464755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM
    Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab.
    Röth A; Dührsen U
    Eur J Haematol; 2011 Dec; 87(6):473-9. PubMed ID: 21883481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria.
    Hill A; Richards SJ; Hillmen P
    Br J Haematol; 2007 May; 137(3):181-92. PubMed ID: 17408457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.
    Keating GM; Lyseng-Williamson KA; McKeage K
    BioDrugs; 2012 Apr; 26(2):125-30. PubMed ID: 22350448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythopoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria.
    Hill A; Richards SJ; Rother RP; Hillmen P
    Haematologica; 2007 Mar; 92(3):e31-3. PubMed ID: 17405753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria.
    Richards SJ; Hill A; Hillmen P
    Cytometry B Clin Cytom; 2007 Sep; 72(5):291-8. PubMed ID: 17549742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
    N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eculizumab: A novel therapy for paroxysmal nocturnal hemoglobinuria.
    Zareba KM
    Drugs Today (Barc); 2007 Aug; 43(8):539-46. PubMed ID: 17925885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition.
    Varela JC; Brodsky RA
    Expert Rev Clin Immunol; 2013 Nov; 9(11):1113-24. PubMed ID: 24168416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of complement inhibition in PNH.
    Hillmen P
    Hematology Am Soc Hematol Educ Program; 2008; ():116-23. PubMed ID: 19074068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paroxysmal nocturnal hemoglobinuria from bench to bedside.
    Pu JJ; Brodsky RA
    Clin Transl Sci; 2011 Jun; 4(3):219-24. PubMed ID: 21707954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How I treat paroxysmal nocturnal hemoglobinuria.
    Brodsky RA
    Blood; 2021 Mar; 137(10):1304-1309. PubMed ID: 33512400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycosylphosphatidylinositol (GPI)-anchored membrane proteins in clinical pathophysiology of paroxysmal nocturnal hemoglobinuria (PNH).
    Shichishima T
    Fukushima J Med Sci; 1995 Jun; 41(1):1-13. PubMed ID: 8606038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.